Kaitlyn D’Onofrio

DocwireNews

<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/doctors-share-reality-of-caring-for-cancer-patients-in-italy-during-covid-19-outbreak/">Cancer patients</a> have been found to have a higher likelihood of <a href="https://www.docwirenews.com/docwire-pick/home-page-picks/the-covid-19-pandemic-cases-spiking-throughout-the-us-johns-hopkins-offers-national-strategy-for-expanding-antibody-testing-and-more/">contracting COVID-19</a>. Researchers recently examined the management and outcomes of these patients. They found that patients on anticancer treatments may have a greater risk for mortality.&ldquo;Currently, several guidelines regarding the management of patients with cancer also have been proposed, but arguably, these are mostly consensus agreements, with little guidance derived from data regarding the outcomes of patients with cancer who are diagnosed with COVID&#8208;19. Examples of some pertinent questions include possible differences in the severity of COVID&#8208;19 between patients with different cancer types and the implications of active anticancer treatment on the clinical presentation, severity, and treatment outcomes of COVID&#8208;19 pneumonia,&rdquo; the study authors wrote.This multicenter, retrospective study included hospitalized patients at five Wuhan City, China, hospitals between Jan. 5 and March 18. Medical records were analyzed for cancer type, cancer treatment, and COVID-19 clinical parameters. The main outcome measure was overall survival. Other outcomes included the association between clinical factors and severe COVID-19 and overall survival.Final analysis included 107 patients diagnosed with COVID-19 (median [range] age, 66 [37-98] years). The most commonly observed cancer types were lung (n=21; 19.6%), gastrointestinal (n=20; 18.7%), and genitourinary (n=20; 18.7%). About a third of patients (n=37; 34.6%) were on active anticancer treatment when they received their COVID-19 diagnosis. The remaining patients (n=70; 65.4%) were on follow-up. Among the total cohort, just over half of patients (n=56; 52.3%) developed severe COVID-19. Patients on anticancer treatment were more likely than those on follow-up to develop severe COVID-19 (64.9% vs. 45.7%); anticancer treatment patients had <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/late-mortality-rates-in-young-cancer-survivors-are-improving-according-to-study/">poorer overall survival</a> compared to follow-up patients (hazard ratio, 3.365; 95% confidence interval, 1.455 to 7.782; P=0.005). The correlation between anticancer treatment and overall survival was independent of exposure to systemic therapy; the case fatality rate for systemic therapy was 33.3%, compared to 43.8% for nonsystemic therapy.The study was published in <a href="https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33042">Cancer</a>.&ldquo;Based on this and other studies, it therefore is imperative to consider the deferment of anticancer treatment, if possible, in patients with cancer who unfortunately are diagnosed with COVID&#8208;19. In the same vein, we reiterate that tight infection control measures are crucial to prevent the risk of virus transmission to patients who are receiving ongoing anticancer treatment,&rdquo; the researchers concluded.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Anticancer Therapy May Increase Mortality Risk in COVID-19

COVID-19

Cancer patients have been found to have a higher likelihood of contracting COVID-19. Researchers recently examined the management and outcomes of these patients. They found ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe